Thiol-disulfide homeostasis as an oxidative stress marker in patients with Graves’ ophthalmopathy

Yüksel, Nilay; Tanriverdi, Burak; İpteç, Betül Özbek; Erel, Özcan

doi:10.1080/01676830.2018.1553191

Cited by 7 publications

(8 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study conducted by Yuksel and cols. included smoking patients under treatment for GD who were not recently diagnosed and identified patients with active GO, and further found their mean SS levels were high and their native SH levels were low, similar to our study, and they found a correlation with CAS (24). However, they did not investigate proptosis.…”

Section: Discussionsupporting

confidence: 84%

Proptosis is associated with thiol-disulfide in patients with Graves’ ophthalmopathy

Acibucu¹,

Ozturk²,

Kizildag³

et al. 2022

Archives of Endocrinology and Metabolism

Self Cite

View full text Add to dashboard Cite

Objective: Graves' ophthalmopathy (GO) is a vision-threatening finding observed in approximately half of Graves' disease patients. The pathophysiology of GO is unclear, and one of the suspected factors is oxidative stress. In our study, we compared the relationship between proptosis and SH-SS in patients diagnosed with GO. Materials and methods: In this prospective study, 40 recently diagnosed Graves' disease patients with proptosis, 40 recently diagnosed Graves' disease patients without GO and 30 healthy individuals with similar demographic characteristics were included. Serum thiol-disulfide (SH-SS) measurements were performed. Eye examinations were performed by a single ophthalmologist to check for the presence of GO, and proptosis values were recorded with a Hertel exophthalmometer. Results: Total SH values were lower in the group with proptosis than in the other groups (p < 0.05). Total and native SH values were lower in patients without proptosis than in the control group (p < 0.05). Total SH, native SH and SS levels were independently associated with proptosis (p < 0.05). According to this analysis, it was found that increasing SS and decreasing total and native SH levels increased the probability of proptosis by 24.4%, 32.7% and 32.4%, respectively. Conclusion: A decrease in SH, which is a natural antioxidant that protects the body against oxidative stress, and an increase in SS are important signs of oxidative damage. Proptosis and SH-SS are closely related in GO. This may help us detect GO and proptosis in Graves' patients. It can also assist in developing new options for preventing and treating GO.

show abstract

Section: Discussionsupporting

confidence: 84%

Proptosis is associated with thiol-disulfide in patients with Graves’ ophthalmopathy

Acibucu¹,

Ozturk²,

Kizildag³

et al. 2022

Archives of Endocrinology and Metabolism

Self Cite

View full text Add to dashboard Cite

show abstract

“…Hypoxia-inducible factor-1α activation has been detected in cigarette smokers developing TED ( 61 ). Thiol-disulfide homeostasis may be disrupted in active TED ( 62 ). The increased oxidative stress in TED has led some investigators to propose therapeutic antioxidants for the disease ( 63 ).…”

Section: Deciphering the Pathogenesis Of Tedmentioning

confidence: 99%

Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease

Smith

2022

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

Context Thyroid eye disease (TED), a vision-threatening and disfiguring autoimmune process, has thwarted our efforts to understand its pathogenesis and develop effective and safe treatments. Recent scientific advances have facilitated improved treatment options. Objective Review historically remote and recent advances in understanding TED. Design/Setting/Participants PubMed was scanned using search terms including thyroid-associated ophthalmopathy, thyroid eye disease, Graves’ orbitopathy, autoimmune thyroid disease, and orbital inflammation. Main outcome measures Strength of scientific evidence, size, scope, and controls of clinical trials/observations. Results Glucocorticoid steroids are widely prescribed systemic medical therapy. They can lessen inflammation-related manifestations of TED but fail to reliably reduce proptosis and diplopia, 2 major causes of morbidity. Other current therapies include mycophenolate, rituximab (anti-CD20 B cell-depleting monoclonal antibody), tocilizumab (interleukin-6 receptor antagonist), and teprotumumab (IGF-I receptor inhibitor). Several new therapeutic approaches have been proposed including targeting prostaglandin receptors, vascular endothelial growth factor, mTOR, and cholesterol pathways. Of potentially greater long-term importance are attempts to restore immune tolerance. Conclusion Despite their current wide use, steroids may no longer enjoy first-tier status for TED as more effective and better tolerated medical options become available. Multiple current and emerging therapies, the rationales for which are rooted in theoretical and experimental science, promise better options. These include teprotumumab, rituximab, and tocilizumab. Restoration of immune tolerance could ultimately become the most effective and safe medical management for TED.

show abstract

“…The diagnosis of this ophthalmopathy primarily leverages the Clinical Activity Score (CAS), a critical tool in assessing the activity level of the disease and informing subsequent treatment pathways 21 . This systematic approach assists in the accurate monitoring and decision-making processes essential for disease management 22,23,24 .…”

Section: Resultsmentioning

confidence: 99%

Seeing Through Graves' Ophthalmopathy: Treatment Efficacy and Quality of Life Enhancement

Castro,

Torres,

Tioda

et al. 2024

JHS

View full text Add to dashboard Cite

Thiol-disulfide homeostasis as an oxidative stress marker in patients with Graves’ ophthalmopathy

Cited by 7 publications

References 31 publications

Proptosis is associated with thiol-disulfide in patients with Graves’ ophthalmopathy

Proptosis is associated with thiol-disulfide in patients with Graves’ ophthalmopathy

Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease

Seeing Through Graves' Ophthalmopathy: Treatment Efficacy and Quality of Life Enhancement

Contact Info

Product

Resources

About